AMEFX
Price
$24.33
Change
+$0.19 (+0.79%)
Updated
Dec 20 closing price
DGIFX
Price
$24.86
Change
+$0.14 (+0.57%)
Updated
Dec 20 closing price
Ad is loading...

AMEFX vs DGIFX

Header iconAMEFX vs DGIFX Comparison
Open Charts AMEFX vs DGIFXBanner chart's image
American Funds Income Fund of Amer F2
Price$24.33
Change+$0.19 (+0.79%)
VolumeN/A
CapitalizationN/A
Disciplined Growth Investors
Price$24.86
Change+$0.14 (+0.57%)
VolumeN/A
CapitalizationN/A
AMEFX vs DGIFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
AMEFX vs. DGIFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMEFX is a Buy and DGIFX is a Hold.

FUNDAMENTALS
Fundamentals
AMEFX has more cash in the bank: 124B vs. DGIFX (559M). AMEFX pays higher dividends than DGIFX: AMEFX (3.73) vs DGIFX (0.67). AMEFX was incepted earlier than DGIFX: AMEFX (16 years) vs DGIFX (13 years). AMEFX is a more actively managed with annual turnover of: 40.00 vs. DGIFX (26.00). AMEFX has a lower initial minimum investment than DGIFX: AMEFX (250) vs DGIFX (10000). AMEFX annual gain was more profitable for investors over the last year : 9.31 vs. DGIFX (1.04). DGIFX (19.52) and AMEFX (19.48) have equivalent 5 years return.
AMEFXDGIFXAMEFX / DGIFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years13 years-
Gain YTD8.4251.820463%
Front LoadN/AN/A-
Min. Initial Investment250100003%
Min. Initial Investment IRAN/AN/A-
Net Assets124B559M22,182%
Annual Yield % from dividends3.730.67557%
Returns for 1 year9.311.04894%
Returns for 3 years5.358.6162%
Returns for 5 years19.4819.52100%
Returns for 10 years32.0558.4255%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PFG77.302.12
+2.82%
Principal Financial Group
HI29.820.75
+2.58%
Hillenbrand
CIO5.450.12
+2.25%
City Office Reit
BLRX0.20N/A
+0.50%
BioLineRx Ltd
PSTX9.450.04
+0.43%
Poseida Therapeutics